113440-58-7

Calicheamicin is extremely toxic to all cells and, in 2000, a CD33 antigen-targeted immunoconjugate N-acetyl dimethyl hydrazide calicheamicin was developed and marketed as targeted therapy against the non-solid tumor cancer acute myeloid leukemia (AML).

Calicheamicins (CLM) is an endiyne antitumor antibiotic isolated from the fermentation broth of the rare Micromonospora actinomycetes.